GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Malta’s CEOs would really love to have one particular set of skills
Crystal ball gazing, anyone?
September 2023 marks the first phase of Mercury Towers opening its doors to the public
Mercury Towers will be fully operational in the first quarter of 2024
Education and sustainable workforce can ensure tourism ‘continues to flourish’ – OZO CEO
Fabio Muscat discusses how education is needed to provide the workforce with the skills and knowledge needed to succeed.
Manfred Galdes appointed Partner at Fenech Farrugia Fiott Legal
He possesses over 20 years of experience in the legal profession, specialising in anti-money laundering regulation and financial crime compliance.
